<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">geriatr</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гериатрической медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Geriatric Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2686-8636</issn><issn pub-type="epub">2686-8709</issn><publisher><publisher-name>Сайт издателя</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37586/2686-8636-4-2025-448-459</article-id><article-id custom-type="elpub" pub-id-type="custom">geriatr-602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГЛАВНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MAIN TOPIC</subject></subj-group></article-categories><title-group><article-title>Ключевые особенности сердечной недостаточности с сохраненной фракцией выброса левого желудочка у мультиморбидных пациентов старшего возраста на фоне старческой астении</article-title><trans-title-group xml:lang="en"><trans-title>Key insights of heart failure with preserved left ventricular ejection fraction in elderly patients with multimorbidity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7825-5597</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларина</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Larina</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ларина Вера Николаевна</p><p>Москва</p></bio><bio xml:lang="en"><p>Larina Vera Nikolaevna</p><p>Moscow</p></bio><email xlink:type="simple">larina_vn@rsmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России (Пироговский Университет)<country>Россия</country></aff><aff xml:lang="en">Pirogov Russian National Research Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2025</year></pub-date><volume>0</volume><issue>4</issue><fpage>448</fpage><lpage>459</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ларина В.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ларина В.Н.</copyright-holder><copyright-holder xml:lang="en">Larina V.N.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.geriatr-news.com/jour/article/view/602">https://www.geriatr-news.com/jour/article/view/602</self-uri><abstract><p>Мультиморбидность, определяемая как сопутствующее наличие более чем одного хронического заболевания, часто сопровождает сердечную недостаточность (СН), особенно с  сохраненной фракцией выброса левого желудочка (ФВ ЛЖ, 50 % и выше), рассматриваемую как гетерогенный клинический синдром, часто встречающийся у  людей старшего возраста с  ослабленным функциональным и  физическим статусом, в основном у женщин, у лиц с артериальной гипертензией, ожирением, сахарным диабетом, фибрилляцией предсердий, ишемической болезнью сердца, хронической болезнью почек. Сопутствующая патология и старческая астения (СА) являются важнейшими детерминантами исходов СН и оказывают значительное влияние на качество жизни. В современном стареющем обществе мультиморбидность является скорее правилом, чем исключением, что ставит перед врачами задачу одновременного лечения СН и сопутствующих заболеваний. Сердечная недостаточность с сохраненной фракцией выброса левого желудочка (СНсФВ) является результатом воздействия многих факторов, в том числе инволютивных изменений в организме на фоне старения, а наиболее частой причиной ее развития является диастолическая дисфункция. Патофизиологические механизмы СНсФВ включают вклад низкоинтенсивного хронического воспаления в развитие эндотелиальной дисфункции микрососудистого русла, оксидативный стресс, способствующие патологическому ремоделированию левого желудочка (ЛЖ) и прогрессированию диастолической дисфункции. Широкий спектр неспецифических симптомов, сопутствующей патологии и СА затрудняют диагностику СН и выбор терапии, положительно влияющей на прогноз. В качестве современных подходов медикаментозного лечения мультиморбидных пациентов старшего возраста с СНсФВ рассматриваются болезнь-модифицирующая терапия, диуретики, инновационные препараты, воздействующие на воспаление.</p></abstract><trans-abstract xml:lang="en"><p>Multimorbidity is defined as the coexistence of more than one chronic disease and is frequently associated with heart failure (HF), particularly in cases with a preserved left ventricular ejection fraction (EF). It is considered a heterogeneous clinical syndrome, especially among elderly individuals with an impaired functional and physical status. It is particularly prevalent in  females and in  individuals with arterial hypertension, obesity, diabetes mellitus, atrial fibrillation, ischemic heart disease and chronic kidney disease. Comorbidity and frailty are important determinants of HF outcomes and significantly impact quality of life. In today's ageing society, multimorbidity is the norm rather than the exception, posing a challenge to physicians who must treat HF and its associated diseases simultaneously. HFpEF results from many factors, including involutional changes in the body due to ageing. The most common cause of its development is diastolic dysfunction. The pathophysiological mechanisms of HFpEF include low-intensity chronic inflammation contributing to microvascular endothelial dysfunction and oxidative stress, which promote pathological left ventricular (LV) remodelling and the progression of diastolic dysfunction. The wide range of non-specific symptoms, concomitant diseases and frailty complicate the diagnosis of heart failure and the selection of an effective therapy. Disease-modifying therapy, diuretics and innovative anti-inflammatory drugs are modern approaches to managing elderly multimorbid patients with HFpEF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мультиморбидность</kwd><kwd>сердечная недостаточность</kwd><kwd>сохраненная фракция выброса левого желудочка</kwd><kwd>пожилой пациент</kwd><kwd>старческая астения</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multimorbidity</kwd><kwd>heart failure</kwd><kwd>preserved left ventricular ejection fraction</kwd><kwd>elderly patient</kwd><kwd>frailty</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bezerra de Souza D. L., Oliveras-Fabregas A., Espelt A., et al. Multimorbidity and its associated factors among adults aged 50 and over: a cross-sectional study in 17 European countries. PLoS One. 2021 ; 16 (2) : e0246623. doi: 10.1371/ journal.pone.0246623.</mixed-citation><mixed-citation xml:lang="en">Bezerra de Souza D. L., Oliveras-Fabregas A., Espelt A., et al. Multimorbidity and its associated factors among adults aged 50 and over: a cross-sectional study in 17 European countries. PLoS One. 2021 ; 16 (2) : e0246623. doi: 10.1371/ journal.pone.0246623.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">National Guideline Centre. Multimorbidity: clinical assessment and management. [Electronic resourse]. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Sep 21 23 p. (NICE guideline; no. 56). Access mode: https://www.nice.org.uk/guidance/ng56, free.</mixed-citation><mixed-citation xml:lang="en">National Guideline Centre. Multimorbidity: clinical assessment and management. [Electronic resourse]. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Sep 21 23 p. (NICE guideline; no. 56). Access mode: https://www.nice.org.uk/guidance/ng56, free.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yang M., Kondo T., Adamson C., et al. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. Eur J Heart Fail. 2023 ; 25 : 1606–1618. doi: 10.1002/ejhf.2962.</mixed-citation><mixed-citation xml:lang="en">Yang M., Kondo T., Adamson C., et al. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. Eur J Heart Fail. 2023 ; 25 : 1606–1618. doi: 10.1002/ejhf.2962.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Галявич А. С., Терещенко С. Н., Ускач Т. М. и др. Хроническая сердечная рекомендации журнал. — 2024. — Т. 29, № 11. — С. 251–349. doi: 10.15829/1560-4071-2024-6162.</mixed-citation><mixed-citation xml:lang="en">Galyavich A. S., Tereshchenko S. N., Uskach T. M., et al. 2024 Clinical practice guidelines Journal of Cardiology. 2024 ; 29 (11) : 6162 (In Russ.). doi: 10.15829/1560-4071-2024-6162.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Поляков Д. С., Фомин И. В., Беленков Ю. Н. и др. Хроническая сердечная недостаточность в Российской Федерации: что Результаты исследования ЭПОХА–ХСН. // Кардиология. — 2021. — Т. 61, № 4. — С. 4–14. doi: 10.18087/cardio.2021.4.n1628.</mixed-citation><mixed-citation xml:lang="en">Polyakov D. S., Fomin I. V., Belenkov Yu. N., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021 ; 61 (4) : 4–14. (In Russ.). doi: 10.18087/cardio.2021.4.n1628.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020 ; 21 (4) : 531–540. doi: 10.31083/j.rcm.2020.04.154.</mixed-citation><mixed-citation xml:lang="en">Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020 ; 21 (4) : 531–540. doi: 10.31083/j.rcm.2020.04.154.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Upadhya B., Kitzman D. W. Heart failure with preserved ejection fraction: New approaches todiagnosis and management. Clin Cardiol. 2020 ; 43 (2) : 145–155. doi: 10.1002/clc.23321.</mixed-citation><mixed-citation xml:lang="en">Upadhya B., Kitzman D. W. Heart failure with preserved ejection fraction: New approaches todiagnosis and management. Clin Cardiol. 2020 ; 43 (2) : 145–155. doi: 10.1002/clc.23321.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Del Pilar Falcón Fleytas R., Centurión O. A., Figueredo J. G., et al. Profile and Prognostic Impact of Multimorbidity in Elderly Patients with Heart Failure: Are there Differences between Men and Women? Curr Heart Fail Rep. 2024 ; 21 (4) : 337–343. doi: 10.1007/s11897-024-00673-x.</mixed-citation><mixed-citation xml:lang="en">Del Pilar Falcón Fleytas R., Centurión O. A., Figueredo J. G., et al. Profile and Prognostic Impact of Multimorbidity in Elderly Patients with Heart Failure: Are there Differences between Men and Women? Curr Heart Fail Rep. 2024 ; 21 (4) : 337–343. doi: 10.1007/s11897-024-00673-x.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tomasoni D., Vitale C., Guidetti F., et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024 ; 26 (4) : 854–868. doi: 10.1002/ejhf.3112.</mixed-citation><mixed-citation xml:lang="en">Tomasoni D., Vitale C., Guidetti F., et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024 ; 26 (4) : 854–868. doi: 10.1002/ejhf.3112.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zile M. R. Heart failure with preserved ejection fraction: is this diastolic heart failure. J Am Coll Cardiol. 2003 ; 41 (9) : 1519–1522. doi: 10.1016/s0735-1097(03)00186-4.</mixed-citation><mixed-citation xml:lang="en">Zile M. R. Heart failure with preserved ejection fraction: is this diastolic heart failure. J Am Coll Cardiol. 2003 ; 41 (9) : 1519–1522. doi: 10.1016/s0735-1097(03)00186-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hunt S. A., Abraham W. T., Chin M. H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 ; 112 (12) : e154–e235. doi: 10.1161/CIRCULATIONAHA.105.167586.</mixed-citation><mixed-citation xml:lang="en">Hunt S. A., Abraham W. T., Chin M. H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 ; 112 (12) : e154–e235. doi: 10.1161/CIRCULATIONAHA.105.167586.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P., Voors A. A., Anker S. D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 ; 37 (27) : 2129–2200. doi: 10.1093/eurheartj/ehw128.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P., Voors A. A., Anker S. D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 ; 37 (27) : 2129–2200. doi: 10.1093/eurheartj/ehw128.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh T. A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 (36) : 3599–3726. doi: 10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh T. A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 ; 42 (36) : 3599–3726. doi: 10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Naing P., Forrester D., Kangaharan N., et al. Heart failure with preserved ejection fraction: A growing global epidemic. Aust J Gen Pract. 2019 ; 48 (7) : 465–471. doi: 10.31128/AJGP-03-19-4873.</mixed-citation><mixed-citation xml:lang="en">Naing P., Forrester D., Kangaharan N., et al. Heart failure with preserved ejection fraction: A growing global epidemic. Aust J Gen Pract. 2019 ; 48 (7) : 465–471. doi: 10.31128/AJGP-03-19-4873.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Anker S. D., Usman M. S., Anker M. S., et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023 ; 25 (7) : 936–955. doi: 10.1002/ejhf.2894.</mixed-citation><mixed-citation xml:lang="en">Anker S. D., Usman M. S., Anker M. S., et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023 ; 25 (7) : 936–955. doi: 10.1002/ejhf.2894.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tahhan A. S., Vaduganathan M., Greene S. J., et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol. 2018 ; 3 (10) : 1011–1019. doi: 10.1001/jamacardio.2018.2559.</mixed-citation><mixed-citation xml:lang="en">Tahhan A. S., Vaduganathan M., Greene S. J., et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol. 2018 ; 3 (10) : 1011–1019. doi: 10.1001/jamacardio.2018.2559.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shah A. M., Cikes M., Prasad N., et al. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 ; 74 (23) : 2858–2873. doi: 10.1016/j.jacc.2019.09.063.</mixed-citation><mixed-citation xml:lang="en">Shah A. M., Cikes M., Prasad N., et al. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 ; 74 (23) : 2858–2873. doi: 10.1016/j.jacc.2019.09.063.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">van Riet E. E., Hoes A. W., Wagenaar K. P., et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016 ; 18 (3) : 242–252. doi: 10.1002/ejhf.483.</mixed-citation><mixed-citation xml:lang="en">van Riet E. E., Hoes A. W., Wagenaar K. P., et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016 ; 18 (3) : 242–252. doi: 10.1002/ejhf.483.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Paulus W. J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 ; 62 (4) : 263–271. doi: 10.1016/j.jacc.2013.02.092.</mixed-citation><mixed-citation xml:lang="en">Paulus W. J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 ; 62 (4) : 263–271. doi: 10.1016/j.jacc.2013.02.092.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Crum Y., Hoendermis E. S., van Veldhuisen D. J., et al. Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction. ESC Heart Fail. 2024 ; 11 (3) : 1698–1706. doi: 10.1002/ehf2.14739.</mixed-citation><mixed-citation xml:lang="en">Crum Y., Hoendermis E. S., van Veldhuisen D. J., et al. Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction. ESC Heart Fail. 2024 ; 11 (3) : 1698–1706. doi: 10.1002/ehf2.14739.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Whitman J., Kozaily E., Michos E. D., et al. Epicardial Fat in Heart Failure and Preserved Ejection Fraction: Novel Insights and Future Perspectives. Curr Heart Fail Rep. 2025 ; 22 (1) : 13 doi: 10.1007/s11897-025-00700-5.</mixed-citation><mixed-citation xml:lang="en">Whitman J., Kozaily E., Michos E. D., et al. Epicardial Fat in Heart Failure and Preserved Ejection Fraction: Novel Insights and Future Perspectives. Curr Heart Fail Rep. 2025 ; 22 (1) : 13 doi: 10.1007/s11897-025-00700-5.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ogawa A., Shimizu K., Nakagami T., et al. Physical function and cardio-ankle vascular index in elderly heart failure patients. Int Heart J. 2020 ; 61 (4) : 769–775. doi: 10.1536/ihj.20-058.</mixed-citation><mixed-citation xml:lang="en">Ogawa A., Shimizu K., Nakagami T., et al. Physical function and cardio-ankle vascular index in elderly heart failure patients. Int Heart J. 2020 ; 61 (4) : 769–775. doi: 10.1536/ihj.20-058.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Archer S. H., Lee C. S., Gupta N., et al. Sex differences in the impact of physical frailty on outcomes in heart failure. Heart Lung. 2023 ; 61 : 66–71. doi: 10.1016/j.hrtlng.2023.04.014.</mixed-citation><mixed-citation xml:lang="en">Archer S. H., Lee C. S., Gupta N., et al. Sex differences in the impact of physical frailty on outcomes in heart failure. Heart Lung. 2023 ; 61 : 66–71. doi: 10.1016/j.hrtlng.2023.04.014.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">de Jorge-Huerta L., Marco-Alacid C., Grande C., Velardo Andrés C. A Narrative Review of the Diagnosis and Treatment of Sarcopenia and Malnutrition in Patients with Heart Failure. Nutrients. 2024 ; 16 (16) : 2717 doi: 10.3390/nu16162717.</mixed-citation><mixed-citation xml:lang="en">de Jorge-Huerta L., Marco-Alacid C., Grande C., Velardo Andrés C. A Narrative Review of the Diagnosis and Treatment of Sarcopenia and Malnutrition in Patients with Heart Failure. Nutrients. 2024 ; 16 (16) : 2717 doi: 10.3390/nu16162717.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Cosiano M. F., Jannat-Khah D., Lin F. R., et al. Hearing Loss and Physical Functioning Among Adults with Heart Failure: Data from NHANES. Clin Interv Aging. 2020 ;15 : 635– 643 doi: 10.2147/CIA.S246662. Erratum in: Clin Interv Aging. 2020 ; 15 : 887 doi: 10.2147/CIA.S265904.</mixed-citation><mixed-citation xml:lang="en">Cosiano M. F., Jannat-Khah D., Lin F. R., et al. Hearing Loss and Physical Functioning Among Adults with Heart Failure: Data from NHANES. Clin Interv Aging. 2020 ;15 : 635– 643 doi: 10.2147/CIA.S246662. Erratum in: Clin Interv Aging. 2020 ; 15 : 887 doi: 10.2147/CIA.S265904.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачева О. Н., Котовская Ю. В., Рунихина Н. К. и др. Клинические рекомендации «Старческая астения». // Российский журнал гериатрической медицины. — 2025. — Т. 1, № 21. — С. 6–48. doi: 10.37586/2686-8636-1-2025-6-48.</mixed-citation><mixed-citation xml:lang="en">Tkacheva O. N., Kotovskaya Yu. V., Runikhina N. K., et al. Clinical guidelines Frailty. Russian Journal of Geriatric Medicine. 2025 ; (1) : 6–48. (In Russ.) doi: 10.37586/2686-8636-1-2025-6-48.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж. Д., Моисеева А. Ю., Ал Аутаири А., Котова Е. О. Особенности течения и прогноза хронической сердечной недостаточности у пациентов с синдромом старческой астении. // Российский кардиологический журнал. — 2025. — Т. 30, № 7 С. 62–68. doi: 10.15829/1560-4071-2025-6299.</mixed-citation><mixed-citation xml:lang="en">Kobalava Zh. D., Moiseeva A. Yu., Al Autairi A., Kotova E. O. Course and prognosis of heart failure in patients with frailty syndrome. Russian Journal of Cardiology. 2025 ; 30 (7) : 6299 (In Russ.) doi: 10.15829/1560-4071-2025-6299.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Uchmanowicz I., Pasieczna A. H., Wójta-Kempa M., et al. Physical, Psychological and Social Frailty Are Predictive of Heart Failure: A Cross-Sectional Study. J Clin Med. 2022 ; 11 (3) : 565 doi: 10.3390/jcm11030565.</mixed-citation><mixed-citation xml:lang="en">Uchmanowicz I., Pasieczna A. H., Wójta-Kempa M., et al. Physical, Psychological and Social Frailty Are Predictive of Heart Failure: A Cross-Sectional Study. J Clin Med. 2022 ; 11 (3) : 565 doi: 10.3390/jcm11030565.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Vitale C., Spoletini I., Rosano G. M. Frailty in Heart Failure: Implications for Management. Card Fail Rev. 2018 ; 4 (2) :104–106. doi: 10.15420/cfr.2018.22.2.</mixed-citation><mixed-citation xml:lang="en">Vitale C., Spoletini I., Rosano G. M. Frailty in Heart Failure: Implications for Management. Card Fail Rev. 2018 ; 4 (2) :104–106. doi: 10.15420/cfr.2018.22.2.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Vitale C., Uchmanowicz I. Frailty in patients with heart failure. Eur Heart J Suppl. 2019 ; 21 (Suppl L) : L12–L16. doi: 10.1093/eurheartj/suz238.</mixed-citation><mixed-citation xml:lang="en">Vitale C., Uchmanowicz I. Frailty in patients with heart failure. Eur Heart J Suppl. 2019 ; 21 (Suppl L) : L12–L16. doi: 10.1093/eurheartj/suz238.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Uchida S., Kamiya K., Yamashita M., et al. Current findings and challenges on frailty, sarcopenia, and cachexia in older patients with heart failure: insights from the FRAGILE-HF study. J Cardiol. 2025 : S0914–5087(25)00138-8. doi: 10.1016/j.jjcc.2025.05.013.</mixed-citation><mixed-citation xml:lang="en">Uchida S., Kamiya K., Yamashita M., et al. Current findings and challenges on frailty, sarcopenia, and cachexia in older patients with heart failure: insights from the FRAGILE-HF study. J Cardiol. 2025 : S0914–5087(25)00138-8. doi: 10.1016/j.jjcc.2025.05.013.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Roalfe A. K., Taylor C. J., Kelder J. C., et al. Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies. ESC Heart Fail. 2021 J ; 8 (3) : 2193–2201. doi: 10.1002/ehf2.13311.</mixed-citation><mixed-citation xml:lang="en">Roalfe A. K., Taylor C. J., Kelder J. C., et al. Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies. ESC Heart Fail. 2021 J ; 8 (3) : 2193–2201. doi: 10.1002/ehf2.13311.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Anjan V. Y., Loftus T. M., Burke M. A., et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012 ; 110 (6) : 870–876. doi: 10.1016/j.amjcard.2012.05.014.</mixed-citation><mixed-citation xml:lang="en">Anjan V. Y., Loftus T. M., Burke M. A., et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012 ; 110 (6) : 870–876. doi: 10.1016/j.amjcard.2012.05.014.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Cleland J. G. F., Pfeffer M. A., Clark A. L., et al. The struggle towards a universal definition of heart failure — how to proceed? Eur Heart J. 2021 ; 42 : 2331–2343. doi: 10.1093/eurheartj/ehab082.</mixed-citation><mixed-citation xml:lang="en">Cleland J. G. F., Pfeffer M. A., Clark A. L., et al. The struggle towards a universal definition of heart failure — how to proceed? Eur Heart J. 2021 ; 42 : 2331–2343. doi: 10.1093/eurheartj/ehab082.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Bayes-Genis A., Docherty K. F., Petrie M. C., et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023 ; 25 (11) : 1891–1898. doi: 10.1002/ejhf.3036</mixed-citation><mixed-citation xml:lang="en">Bayes-Genis A., Docherty K. F., Petrie M. C., et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023 ; 25 (11) : 1891–1898. doi: 10.1002/ejhf.3036</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy Y., Carter R., Obokata M. et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018 ; 138 (9) : 861–870 doi: 10.1161/circulationaha.118.034646.</mixed-citation><mixed-citation xml:lang="en">Reddy Y., Carter R., Obokata M. et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018 ; 138 (9) : 861–870 doi: 10.1161/circulationaha.118.034646.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Pieske B., Tschöpe C., de Boer R., et al. How to diagnose heart failure with preserved ejection fraction: The HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 ; 40 (40) : 3297–3317. doi: 10.1002/ejhf.1741.</mixed-citation><mixed-citation xml:lang="en">Pieske B., Tschöpe C., de Boer R., et al. How to diagnose heart failure with preserved ejection fraction: The HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 ; 40 (40) : 3297–3317. doi: 10.1002/ejhf.1741.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачева О. Н., Котовская Ю. В., Рунихина Н. К. и др. Актуальность использования кардиопульмонального нагрузочного тестирования у пациентов пожилого и старческого возраста. // Российский журнал гериатрической медицины. — 2023. — № 1. — С. 44–53. doi: 10.37586/2686-8636-1-2023-44-53.</mixed-citation><mixed-citation xml:lang="en">Tkacheva O. N., Kotovskaya Yu. V., Runikhina N. K., et al. The relevance of the use of cardiopulmonary exercise testing (CPET) in elderly and senile patients. Russian Journal of Geriatric Medicine. 2023 ; (1) : 44–53. (In Russ.). doi: 10.37586/2686-8636-1-2023-44-53.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Kawashima K., Hirashiki A., Nomoto K., et al. Peak work rate during exercise could detect frailty status in elderly patients with stable heart failure. Int Heart J. 2019 ; 60 (6) : 1366–1372. doi: 10.1536/ihj.19-120.</mixed-citation><mixed-citation xml:lang="en">Kawashima K., Hirashiki A., Nomoto K., et al. Peak work rate during exercise could detect frailty status in elderly patients with stable heart failure. Int Heart J. 2019 ; 60 (6) : 1366–1372. doi: 10.1536/ihj.19-120.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Котовская Ю. В., Розанов А. В., Курашев Д. Х., Ткачева О. Н. Сердечная недостаточность и синдром старческой астении. // Медицинский Совет. — 2018 № 16. — С. 72–79. doi: 10.21518/2079-701X-2018-16-72-79.</mixed-citation><mixed-citation xml:lang="en">Kotovskaya Y. V., Rozanov A. V., Kurashev D. H., Tkacheva O. N. Heart failure and senile asthenia syndrome. Meditsinskiy sovet = Medical Council. 2018 ; (16) : 72–79. (In Russ.). doi: 10.21518/2079-701X-2018-16-72-79.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеева А. Ю., Кобалава Ж. Д. Клинические характеристики хронической сердечной недостаточности в зависимости от выраженности доменов синдрома старческой астении. // Российский журнал гериатрической медицины. — 2025. — № 2. — С. 212–214. doi: 10.37586/2686-8636-2-2025-212-214.</mixed-citation><mixed-citation xml:lang="en">Moiseeva A. Yu., Kobalava Zh. D. Clinical characteristics of chronic heart failure depending on the severity of the domains of senile asthenia syndrome. Russian Journal of Geriatric Medicine. 2025 ; (2) : 212–214. (In Russ.). doi: 10.37586/2686-8636-2-2025-212-214.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Концевая А. В., Калинина А. М и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022 // Кардиоваскулярная терапия и профилактика. — 2022. — Т. 21, № 4. — С. 5–232. doi: 10.15829/1728-8800-2022-3235.</mixed-citation><mixed-citation xml:lang="en">Drapkina O. M., Kontsevaya A. V., Kalinina A. M., et al. 2022 Prevention of chronic noncommunicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022 ; 21 (4) : 3235 (In Russ.). doi: 10.15829/1728-8800-2022-3235.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Verma S., Mudaliar S., Greasley P. J. Potential underlying mechanisms explaining the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors. Adv Ther. 2024 ; 41 (1) : 92–112. doi: 10.1007/s12325-023-02652-5.</mixed-citation><mixed-citation xml:lang="en">Verma S., Mudaliar S., Greasley P. J. Potential underlying mechanisms explaining the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors. Adv Ther. 2024 ; 41 (1) : 92–112. doi: 10.1007/s12325-023-02652-5.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Elgendy I. Y., Mahtta D., Pepine C. J. Medical therapy for heart failure caused by ischemic heart disease. Circ Res. 2019; 124 (11) : 1520–1535. doi: 10.1161/CIRCRESAHA.118.313568.</mixed-citation><mixed-citation xml:lang="en">Elgendy I. Y., Mahtta D., Pepine C. J. Medical therapy for heart failure caused by ischemic heart disease. Circ Res. 2019; 124 (11) : 1520–1535. doi: 10.1161/CIRCRESAHA.118.313568.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Pieske B., Wachter R., Shah S. J., et al. Effect of Sacubitril/ Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021 ; 326 (19) : 1919–1929. doi: 10.1001/jama.2021.18463.</mixed-citation><mixed-citation xml:lang="en">Pieske B., Wachter R., Shah S. J., et al. Effect of Sacubitril/ Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021 ; 326 (19) : 1919–1929. doi: 10.1001/jama.2021.18463.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Vaduganathan M., Docherty K. F., Claggett B. L., et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 ; 400 (10354) : 757–767. doi: 10.1016/ S0140-6736(22)01429-5.</mixed-citation><mixed-citation xml:lang="en">Vaduganathan M., Docherty K. F., Claggett B. L., et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 ; 400 (10354) : 757–767. doi: 10.1016/ S0140-6736(22)01429-5.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Sindone A., Abdelhamid M., Almahmeed et al. An international modified Delphi consensus study on the optimal diagnosis and treatment of patients with HFpEF. Curr Med Res Opin. 2025 ; 41 (3) : 385–395. doi: 10.1080/03007995.2025.2480736.</mixed-citation><mixed-citation xml:lang="en">Sindone A., Abdelhamid M., Almahmeed et al. An international modified Delphi consensus study on the optimal diagnosis and treatment of patients with HFpEF. Curr Med Res Opin. 2025 ; 41 (3) : 385–395. doi: 10.1080/03007995.2025.2480736.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kapelios C. J., Murrow J. R., Nührenberg T. G., Montoro Lopez M. N. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2019 ; 24 (3) : 367–377. doi: 10.1007/s10741-018-9758-0.</mixed-citation><mixed-citation xml:lang="en">Kapelios C. J., Murrow J. R., Nührenberg T. G., Montoro Lopez M. N. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2019 ; 24 (3) : 367–377. doi: 10.1007/s10741-018-9758-0.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon S. D., McMurray J. J. V., Vaduganathan M., et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024 ; 391 (16) : 1475–1485. doi: 10.1056/NEJMoa2407107.</mixed-citation><mixed-citation xml:lang="en">Solomon S. D., McMurray J. J. V., Vaduganathan M., et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024 ; 391 (16) : 1475–1485. doi: 10.1056/NEJMoa2407107.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Ostrominski J. W., Filippatos G., Claggett B. L., et al. Efficacy and safety of finerenone in heart failure with preserved ejection fraction: a FINE-HEART analysis. JACC Heart Fail. 2025 ; 13 (8) : 102497 doi: 10.1016/j.jchf.2025.03.041.</mixed-citation><mixed-citation xml:lang="en">Ostrominski J. W., Filippatos G., Claggett B. L., et al. Efficacy and safety of finerenone in heart failure with preserved ejection fraction: a FINE-HEART analysis. JACC Heart Fail. 2025 ; 13 (8) : 102497 doi: 10.1016/j.jchf.2025.03.041.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Kosiborod M. N., Verma S., Borlaug B. A., et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024 ; 149 (3) : 204–216. doi: 10.1161/ CIRCULATIONAHA.123.067505.</mixed-citation><mixed-citation xml:lang="en">Kosiborod M. N., Verma S., Borlaug B. A., et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024 ; 149 (3) : 204–216. doi: 10.1161/ CIRCULATIONAHA.123.067505.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kosiborod M. N., Abildstrøm S. Z., Borlaug B. A., et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 ;389 (12) : 1069–1084. doi: 10.1056/NEJMoa2306963.</mixed-citation><mixed-citation xml:lang="en">Kosiborod M. N., Abildstrøm S. Z., Borlaug B. A., et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 ;389 (12) : 1069–1084. doi: 10.1056/NEJMoa2306963.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Butt J. H., Heckman G. A. Frailty and semaglutide in obesity-related HFpEF: another STEP in the right direction. JACC Heart Fail. 2025 ; 13 (10) : 102643 doi: 10.1016/j.jchf.2025.102643.</mixed-citation><mixed-citation xml:lang="en">Butt J. H., Heckman G. A. Frailty and semaglutide in obesity-related HFpEF: another STEP in the right direction. JACC Heart Fail. 2025 ; 13 (10) : 102643 doi: 10.1016/j.jchf.2025.102643.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Lund L. H., Lam C. S. P., Pizzato P. E., et al. Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction. Eur J Heart Fail. 2023; 25(9):1696-1707. doi: 10.1002/ejhf.2977.</mixed-citation><mixed-citation xml:lang="en">Lund L. H., Lam C. S. P., Pizzato P. E., et al. Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction. Eur J Heart Fail. 2023; 25(9):1696-1707. doi: 10.1002/ejhf.2977.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Lam C. S. P., Lund L. H., Shah S. J., et al. Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results. J Card Fail. 2024 ; 30 (1) : 104–110. doi: 10.1016/j.cardfail.2023.04.003.</mixed-citation><mixed-citation xml:lang="en">Lam C. S. P., Lund L. H., Shah S. J., et al. Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results. J Card Fail. 2024 ; 30 (1) : 104–110. doi: 10.1016/j.cardfail.2023.04.003.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
